JP2014523398A - 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 - Google Patents

抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 Download PDF

Info

Publication number
JP2014523398A
JP2014523398A JP2014501258A JP2014501258A JP2014523398A JP 2014523398 A JP2014523398 A JP 2014523398A JP 2014501258 A JP2014501258 A JP 2014501258A JP 2014501258 A JP2014501258 A JP 2014501258A JP 2014523398 A JP2014523398 A JP 2014523398A
Authority
JP
Japan
Prior art keywords
integrin
beta
antibody
agent
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014501258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523398A5 (cg-RX-API-DMAC7.html
Inventor
ショーン カーボネル ウォーレン
クマール アギー マニッシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2014523398A publication Critical patent/JP2014523398A/ja
Publication of JP2014523398A5 publication Critical patent/JP2014523398A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014501258A 2011-03-23 2012-03-22 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 Pending JP2014523398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466791P 2011-03-23 2011-03-23
US61/466,791 2011-03-23
PCT/US2012/030204 WO2012129448A1 (en) 2011-03-23 2012-03-22 Methods and compositions for improving antiangiogenic therapy with anti-integrins

Publications (2)

Publication Number Publication Date
JP2014523398A true JP2014523398A (ja) 2014-09-11
JP2014523398A5 JP2014523398A5 (cg-RX-API-DMAC7.html) 2015-05-07

Family

ID=46879749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501258A Pending JP2014523398A (ja) 2011-03-23 2012-03-22 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物

Country Status (9)

Country Link
US (3) US20140079637A1 (cg-RX-API-DMAC7.html)
EP (1) EP2688585B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014523398A (cg-RX-API-DMAC7.html)
KR (1) KR20140030153A (cg-RX-API-DMAC7.html)
CN (1) CN103561761A (cg-RX-API-DMAC7.html)
AU (1) AU2012230809B2 (cg-RX-API-DMAC7.html)
CA (1) CA2830908C (cg-RX-API-DMAC7.html)
ES (1) ES2699532T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012129448A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519342A (ja) * 2019-01-10 2022-03-23 エスジー メディカル インコーポレイテッド 抗ベータ１インテグリンヒト化抗体及びこれを含む癌治療用薬学組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523398A (ja) * 2011-03-23 2014-09-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物
EP2938359A4 (en) * 2012-12-26 2016-10-12 Oncosynergy Inc ANTI-INTEGRIN BETA1 ANTIBODY COMPOSITIONS AND METHODS OF USE
EP3067369A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the treatment of anti-angiogenic resistant cancer
EP3067698A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer
JP7056932B2 (ja) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用
HRP20211627T1 (hr) * 2015-09-17 2022-02-04 Histide Ag Farmaceutski pripravak koji se sastoji od agonista receptora čimbenika rasta i proteina inhibitora adhezije za pretvaranje neoplastične stanice u neneoplastičnu stanicu i njegova upotreba
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514605A (ja) * 1998-05-08 2002-05-21 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 血管形成を検出および阻害する方法
WO2005117976A2 (en) * 2004-06-03 2005-12-15 The Regent Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
JP2007210968A (ja) * 2006-02-10 2007-08-23 Keio Gijuku 神経幹細胞の増殖抑制剤
WO2009009114A2 (en) * 2007-07-12 2009-01-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20090124976A1 (en) * 2007-11-14 2009-05-14 Stephan Mittermeyer Drug supply system for ced (convection-enhanced delivery) catheter infusions
JP2009536921A (ja) * 2006-03-21 2009-10-22 ジェネンテック・インコーポレーテッド アルファ５ベータ１アンタゴニストを含むコンビナトリアル療法
US20100048677A1 (en) * 2008-08-20 2010-02-25 Mitchell W Beau Regulation of Integrin Surface Expression
WO2010072741A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR
WO2010111254A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
US5840300A (en) 1995-09-11 1998-11-24 Trustees Of The University Of Pennsylvania Methods and compositions comprising single chain recombinant antibodies
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6596276B1 (en) 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6716410B1 (en) 1999-10-26 2004-04-06 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
JP3789066B2 (ja) 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
US8725620B2 (en) 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
AU2002312566A1 (en) 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
CA2466762A1 (en) 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
CN102816113B (zh) 2003-07-23 2015-05-13 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
BRPI0507373A (pt) 2004-01-23 2007-07-10 Amgen Inc compostos e método de uso
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN101448858B (zh) * 2006-03-21 2013-06-12 健泰科生物技术公司 牵涉α5β1拮抗剂的联合疗法
EP2066689A4 (en) * 2006-09-07 2010-04-28 Univ South Florida HYD1-PEPTIDE AS ANTICREMENT
WO2009018226A2 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
JP2014523398A (ja) * 2011-03-23 2014-09-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物
EP2938359A4 (en) * 2012-12-26 2016-10-12 Oncosynergy Inc ANTI-INTEGRIN BETA1 ANTIBODY COMPOSITIONS AND METHODS OF USE

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514605A (ja) * 1998-05-08 2002-05-21 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 血管形成を検出および阻害する方法
WO2005117976A2 (en) * 2004-06-03 2005-12-15 The Regent Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
JP2007210968A (ja) * 2006-02-10 2007-08-23 Keio Gijuku 神経幹細胞の増殖抑制剤
JP2009536921A (ja) * 2006-03-21 2009-10-22 ジェネンテック・インコーポレーテッド アルファ５ベータ１アンタゴニストを含むコンビナトリアル療法
WO2009009114A2 (en) * 2007-07-12 2009-01-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20090124976A1 (en) * 2007-11-14 2009-05-14 Stephan Mittermeyer Drug supply system for ced (convection-enhanced delivery) catheter infusions
US20100048677A1 (en) * 2008-08-20 2010-02-25 Mitchell W Beau Regulation of Integrin Surface Expression
WO2010072741A1 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR
WO2010111254A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 66(3), (2006 Feb), JPN6016003742, pages 1526 - 1535, ISSN: 0003249314 *
INT J CANCER., VOL.76, 1998, P.63-72, JPN6016038954, ISSN: 0003416211 *
日本臨床, vol. Vol.68, No.10 (2010), JPN6016003740, pages 1825 - 1829, ISSN: 0003249313 *
松下晃ら: "膵癌においてNeuropilin‐1はintegrin beta 1との関連し,その増殖,生存,浸潤に関与する", 日本癌学会学術総会記事, vol. Vol.67th (2008.09.30), JPN6016003737, pages 195, ISSN: 0003249312 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519342A (ja) * 2019-01-10 2022-03-23 エスジー メディカル インコーポレイテッド 抗ベータ１インテグリンヒト化抗体及びこれを含む癌治療用薬学組成物
JP7222104B2 (ja) 2019-01-10 2023-02-14 エスジー メディカル インコーポレイテッド 抗ベータ１インテグリンヒト化抗体及びこれを含む癌治療用薬学組成物

Also Published As

Publication number Publication date
AU2012230809B2 (en) 2017-06-29
US20180236073A1 (en) 2018-08-23
US20220111045A1 (en) 2022-04-14
KR20140030153A (ko) 2014-03-11
EP2688585A1 (en) 2014-01-29
ES2699532T3 (es) 2019-02-11
WO2012129448A1 (en) 2012-09-27
CA2830908C (en) 2019-09-24
CA2830908A1 (en) 2012-09-27
EP2688585A4 (en) 2015-05-06
AU2012230809A1 (en) 2013-10-10
US20140079637A1 (en) 2014-03-20
CN103561761A (zh) 2014-02-05
US11185585B2 (en) 2021-11-30
EP2688585B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
US20220111045A1 (en) Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP7011574B2 (ja) Ｆｌｔ３及びｃｄ３に対する抗体構築物
CN102596998B (zh) 血管增殖病症的治疗
JP2024099673A (ja) 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
US10106601B2 (en) Inhibition of PLGF to treat philadelphia chromosome positive leukemia
US20090017011A1 (en) Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis
US20120189635A1 (en) Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
CN115873110A (zh) 抑制scube2，一种新颖vegfr2辅助受体，抑制肿瘤血管发生
US20200330591A1 (en) Treatment
JP2025540215A (ja) Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
WO2025240287A1 (en) Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
KR102207221B1 (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법
WO2023105528A1 (en) Antibodies specific to ceacam1
JP2025517336A (ja) 転移性去勢抵抗性前立腺癌を二重特異性抗ｐｓｍａ×抗ＣＤ３抗体を単独で、又は抗ＰＤ－１抗体と組み合わせて治療する方法
JP2021504492A (ja) 癌治療のための組成物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171003